Mozart Therapeutics, Inc.’s Post

Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease: A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials https://lnkd.in/dGMgqgMm

Don’t Miss the NACE On-Demand Course: Non-Statin Lipid Management – It’s All About Risk. This CME webcast explores non-statin lipid management for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in high-risk patients. Dr. Jessica Pena delves into case studies, discussing lipid management in primary hypercholesterolemia, diabetes, and with other risk enhancers, utilizing risk calculators to guide therapy decisions. Learn how to navigate guidelines and expert recommendations to choose the right non-statin therapy, including ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran, for optimal patient outcomes. Don’t miss the NACE On-Demand Course: https://bit.ly/3VXlykc

Evaluation of glucagon-like peptide-1 receptor agonists (#GLP1-RA) in systemic #lupus erythematosus patients (SLE), data from the NYU Lupus Cohort 🔹GLP1-RAs were rarely used in SLE patients ―of 1211 patients in the cohort, only 24 had received a GLP1-RA― and were not associated with increased disease flares. 🔹GLP1-RAs were associated with a significant reduction in BMI after 1-4 months and 6-10 months of use. 🔹GLP1-RAs may be useful adjunctive agents for cardiovascular risk modification in SLE patients. 🔗https://lnkd.in/d79TY_Uy

New Publication Alert 🚨 “Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis” in the prestigious journal Therapeutic Advances in Cardiovascular Disease. Our findings of 16,509 patients highlight that SGLT2 inhibitors significantly reduce hospitalizations but not death in patients with heart failure with preserved ejection fraction (HFpEF), regardless of baseline eGFR, SBP, atrial fibrillation/flutter, diabetes mellitus, sex, BMI, or nt-proBNP levels. https://lnkd.in/dTZx52EY

α1−ANTITRYPSIN DEFICIENCY is an Autosomal recessive disease→↓Hepatocyte α1−antitrypsin, being an enzyme which normally protects organs (esp. the Lungs & Liver) from inflammatory proteolytic digestion (esp. Leukocyte Elastases & Proteases) Plasma levels <10% of normal→relatively ↑proteolytic activity→PREMATURE EMPHYSEMA (age <50 years), esp. if the patient smokes It is estimated that only 10% of patients w/ α1−antitrypsin deficiency are diagnosed Consider the diagnosis in: •Non−smokers •Young patients (age <50 years) •Those w/ concomitant Liver disease knowmedicine.net

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an epidemic that has already reached us and requires close monitoring. In the long term it is associated ☠ With two- to three-fold increase in the risk of death from liver problems and hepatocellular carcinoma. 👯 At least 6 to 7 people out of every 10 people with type 2 diabetes may have this condition. Research and appropriate public policies will allow its control. https://lnkd.in/g-hhPgv5

Comings and Goings: Researchers detail data from First 15 autoimmune disease patients treated with CAR-T (NEJM) In these case studies 15 patients with systemic lupus erythematosus (8 patients), idiopathic inflammatory myositis (3 patients), or systemic sclerosis (4 patients) who received a single infusion of CD19 chimeric antigen receptor (CAR) T cells after preconditioning with fludarabine and cyclophosphamide were followed for up to 2 years (12-15 mo median). Overall, CD19 CAR T-cell transfer appeared to be feasible, safe, and efficacious across three different autoimmune diseases, potentially providing rationale/promise for further controlled clinical trials. see Article: https://lnkd.in/ebjFcEex https://lnkd.in/eVmXe2Wx

DPP-4 Inhibitors & CARDIO-RENAL Outcomes Trials 📑💊 #2 💡EXAMINE Trial💡 This trial showed that treatment with alogliptin resulted in similar rates of MACE to placebo among patients with T2DM and cardiovascular disease OR cardiovascular risk factors.

Efficacy and Safety of Combination Therapy with Low-Dose Rivaroxaban in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Tommaso Bucci et al. J. Clin. Med. 2024, 13, 2033. https://lnkd.in/dfgzyksZ https://lnkd.in/d8_qJBPt Nearly 40% of patients diagnosed with CAD (coronary artery disease) simultaneously have PAD (peripheral artery disease), while approximately 50% of those diagnosed with PAD also have CAD. This is why the use of low-dose rivaroxaban (2.5 mg twice daily) + ASA significantly reduces strokes and systemic embolisms with a small increase in non-fatal extracerebral hemorrhages in patients suffering from high-risk coronary artery disease and/or have had revascularization procedures or in those who have severe PAD, with revascularization and/or risks of lower limb amputations.